AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 62 min read$CL

Wallace Noel R. sold $29.7M of CL

Wallace Noel R. (Chairman, President & CEO) sold 322,042 shares of COLGATE PALMOLIVE CO (CL) at an average of $92.22 ($91.92–$92.52, $29.70M total) across 2 trades over 2026-08-04 to 2026-08-05.

Original reporting
SEC EDGAR · Wallace Noel R.
Published Aug 6, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 7:42 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CL
Neutral
medium confidence
Mentioned
$CL
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLNeutralLow
01

Why it matters

The disclosure updates the record of insider ownership and may influence short-term sentiment, but it does not provide new information about earnings, guidance, or business performance.

02

Market read

Traders may monitor CL for sentiment effects from insider selling, but the filing alone is unlikely to drive a durable repricing.

03

What to watch

No 10b5-1 plan details are provided in the text, and insider sales often have non-informational motives; traders should avoid over-weighting without corroborating fundamentals or guidance changes.

Relevance 7/10Novelty 5/10Timing: Form 4 filed 2026-08-06, covering sales on 2026-08-04 to 2026-08-05.

Background

The article is a SEC Form 4 insider transaction disclosure for Colgate-Palmolive (CL) by its Chairman, President and CEO.

Company-level read

Ticker impact

$CLNeutralMedium confidence
Context

Colgate-Palmolive CEO Wallace Noel R. sold 322,042 shares in open-market transactions totaling about $29.7M, per Form 4 filed Aug. 6.

Expected impact

Low near-term impact; any move is likely sentiment-driven and should fade unless accompanied by other news.

Evidence & confidence

The filing is a routine Form 4 open-market sale with no 10b5-1 plan disclosed and no accompanying operational or guidance change in the text.

Market effects

Sector

Minimal. Large-cap consumer staples insider sales are typically not sector-moving without additional company-specific catalysts.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale could be planned liquidity management rather than a bearish signal, especially given the multi-day execution window.

Key entities

  • issuer
    Colgate-Palmolive Co

    Subject of the Form 4 insider sale disclosure.

  • insider
    Wallace Noel R.

    Chairman, President and CEO who sold 322,042 shares for about $29.7M.

Read at source← All news

Related articles

AUG 4
$CLMed

Colgate-Palmolive Reaffirms Sales Forecast On Weak Demand

Colgate-Palmolive reaffirmed its annual net sales forecast despite a quarterly rise, citing weak North America demand. In the quarter ended June 30, net sales rose 4.9% to $5.36 billion and adjusted EPS was 99 cents. North America organic sales fell 3%, with volumes down 3.9%. The company expects 2026 adjusted earnings growth in mid-single digits and warned tariffs could offset refunds.

checkout.ie3 min
AUG 3
$CLMed

Colgate-Palmolive: Base Business EPS Increases 8% As Gross Margin Expands 140 Basis Points

Colgate-Palmolive reported Q2 2026 Base Business diluted EPS up 8% to $0.99 from $0.92, driven by 140 bps gross-margin expansion to 61.5% and higher organic sales. Reported diluted EPS fell 5% to $0.86 due to $129m pretax charges tied to its Strategic Growth and Productivity Program. Net sales rose 4.9% to $5.36b. Full-year organic outlook 1% to 4%; Base Business EPS expected mid-single-digit growth.

pulse2.com4 min
JUL 31
$CLMed

Colgate-Palmolive Q2 Earnings Call Highlights

Colgate-Palmolive (NYSE:CL) CFO Stan Sutula said Q2 material costs were slightly below expectations due to higher raw-material costs offset by tariff refunds, with no meaningful additional refunds expected. Management now expects full-year gross margin roughly flat, and warned second-half raw-material and tariff costs will be higher. It plans elevated ad spending and North America share recovery; Hill’s organic sales rose 4% excluding discontinued private-label.

yahoo.com4 min
JUL 31
$CLHighAI 9/10

Colgate-Palmolive Q2 2026 slides: strong results fuel raised guidance

Colgate-Palmolive (NYSE:CL) reported Q2 2026 results on July 31. Net sales rose 4.9% to $5.36B and organic sales grew 2.4%. Base EPS increased 8% and free cash flow rose 18% YoY to $1.5B YTD. The company raised 2026 guidance, including flat gross margin outlook and higher EPS growth, and projected $350M to $550M pre-tax charges for its 2030 program.

investing.com6 min
JUL 31
$CLMed

Colgate-Palmolive Lifts FY26 Adj. Earnings View, Despite Weak Q2 Profit; Stock Down

Colgate-Palmolive reported Q2 net earnings of $693 million, down from $743 million a year earlier, with EPS falling to $0.86 from $0.91. Net sales rose to $5.361 billion. The company confirmed FY2026 outlook and raised Base Business EPS growth to mid-single-digit from low- to mid-single-digit, and expects gross margin roughly flat. Shares were down about 2.78% premarket.

finanznachrichten.de4 min